A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
The DOI matches its Crossref record; 56 of the 59 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obsessive-compulsive disorder (OCD) is a common debilitating psychiatric illness that typically improves but does not remit with first-line medication and behavioral treatments. Serotonergic agents including selective serotonin reuptake inhibitors and clomipramine have provided the mainstay of OCD medication management for decades. Combined dopamine/serotonergic agents such as atypical antipsychotics are presently the only OCD-augmenting strategies proven effective via randomized controlled trials. Despite increasing evidence for a pathogenic role of glutamate in OCD, no controlled trials of glutamatergic augmenting agents have been reported. METHODS: An intent-to-treat sample included 44 subjects receiving standard treatment at the McLean/Massachusetts General Hospital Intensive Residential Treatment (IRT) program, 22 of whom also received memantine augmentation. Admission, monthly and discharge measures of OCD, depression, and psychosocial functioning were collected by raters blinded to augmentation status. Matched controls were selected based on sex, initial OCD severity, psychosocial functioning, and timing of admission. The Clinical Global Improvement Scale captured global clinical change. RESULTS: Mean (SD) Yale-Brown Obsessive Compulsive Scale score decreases were 7.2 (6.4) among the cases and 4.6 (5.9) among the matched controls, reflecting mean clinical improvement among the cases (27.0% decrease) but not the controls (16.5% decrease). Mean (SD) depression severity score decreases were 5.8 (9.5) among the cases and 4.7 (9.9) among the controls. Initial intrusive obsessions were significantly more severe among marked responders compared with limited response or nonresponse cases (4.4 vs 2.9; t = 2.15; P = 0.048). CONCLUSIONS: This study provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD. Future randomized double-blind placebo-controlled trials are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Memantine add-on to fluvoxamine significantly improved short-term outcomes in patients with moderate to severe OCD”
From The neurobiological link between OCD and ADHD (2014) · cites this paper as Stewart et al. 2010
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · cited 1×
“76, sensitivity of 100%, and specificity of 89% (using a cutoff score of 16).(22,40,41) The Obsessive-Compulsive Rating scale is a questionnaire-based measure that rates the severity of OCD symptom categories between 0 and 10.”
BackgroundThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712 · cited 1×
“67)(38) with excellent reliability.(38,39) The Y-BOCS checklist has more than 60 items organized into 2 miscellaneous categories and 13 other categories according to thematic content.”
BackgroundThe Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799 · cited 1×
“67)(38) with excellent reliability.(38,39) The Y-BOCS checklist has more than 60 items organized into 2 miscellaneous categories and 13 other categories according to thematic content.”
BackgroundThe Work and Social Adjustment Scale: a simple measure of impairment in functioning
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. M. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.461 · Cited by 2,515 · cited 1×
“86, and increasing scores that reflect worse functional impairment.(43) The Clinical Global Impression (CGI) scale provides an assessment of overall impact of treatment rated between 1 (very much improved) and 7 (very much worse).”
BackgroundThe Yale-Brown Obsessive-Compulsive Scale: Measures of internal consistency
Kim, S. W., Dysken, M. W., Pheley, A. M., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,359
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048 · cited 1×
“First-line OCD treatments, including selective serotonin reuptake inhibitors (SSRIs), cognitivebehavior therapy (CBT), and their combination, are effective in approximately 42% to 50%,(3) 62%, and 70% of cases, respectively.(4) However, symptoms often persist and full remission is uncommon with first-line approaches.”
BackgroundCortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice
Welch, J. M., Lu, J., Rodriguiz, R. M., Trotta, N. C., Peca, J., Ding, J.-D., Feliciano, C., Chen, M., Adams, J. P., Luo, J., et al. (2007) · Nature · doi:10.1038/nature06104 · Cited by 852 · cited 1×
“Knockout mice for the striatum-expressed SAPAP3 gene, coding for a postsynaptic scaffolding protein at corticostriatal glutamatergic excitatory synapses, also developed facial lesions, repetitive grooming behaviors, and anxiety that were reversed with an SSRI and with gene replacement.(33) Memantine is a glutamate rec…”
BackgroundSynopsis of Psychiatry: 5th edn. Behavioral Sciences Clinical Psychiatry
Kaplan, H. I., & Sadock, B. J. (1989) · International Clinical Psychopharmacology · doi:10.1097/00004850-198907000-00008 · Cited by 852
Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder
Saxena, S., & Rauch, S. L. (2000) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70181-7 · Cited by 840 · cited 1×
“24 Moreover, glutamate receptor antagonism leads to an enhancement of 5-HT2A receptorYmediated transmission; 5-HT2A agonism leads to reduced glutamatergic transmission(24) and 5-HT receptor activation reduces the excitatory effect of glutamate on cellular activity.(50) It is this interaction that is believed to contri…”
Background
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adjunctive lamotrigine [799,800] 2 Adjunctive memantine [622,781-783] 2”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…obsessive-compulsive disorder include monotherapy with once-weekly morphine [I (PCT)] (Koran et al., 2005); and the glutamate-modulating compounds riluzole [III] (Coric et al., 2005; Pittenger et al., 2008), memantine [III] (Stewart et al., 2010), and glycine [I (PCT)(Greenberg et al., 2009).”
BackgroundPittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“…below, genetic studies have suggested an association between polymorphisms in the NMDA NR2B subunit and OCD risk (Arnold et al., 2004), and early pharmacological studies with the NMDA-blocking drug memantine have shown promise (Aboujaoude et al., 2009; Feusner et al., 2009; Stewart et al., 2010).”
BackgroundRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
“…and memantine) have been shown to ameliorate OCD symptoms in open (Aboujaoude et al , 2009; Coric et al , 2005; Feusner et al , 2009; Lafleur et al , 2006; Pittenger et al , 2011; Rodriguez et al , 2010; Stewart et al , 2010) and controlled trials (Afshar et al , 2012; Ghaleiha et al , 2013).”
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Metadata
- Authors
- Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A.
- Affiliations
- Harvard University (US)
- McLean Hospital (US)
- Tufts University (US)
- Corresponding author
- Stewart, S. Evelyn
- Jenike, Eric A.
- Hezel, Dianne M.
- Stack, Denise Egan
- Jenike, Michael A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2010-02
- Volume
- 30
- Issue
- 1
- Pages
- 34-39
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2056828397
- Cited by
- 158
- References
- 59
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 2 · 2019: 9 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 11 · 2014: 13 · 2013: 18 · 2012: 14
- FWCI
- 21.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- memantine, obsessive-compulsive disorder, drug augmentation, depression severity, Yale-Brown Obsessive Compulsive Scale, treatment response
- MeSH terms
- Adult, Benzodiazepines, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Inpatients, Male, Memantine, Obsessive-Compulsive Disorder, Residential Facilities, Antipsychotic Agents, Case-Control Studies, Single-Blind Method, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181c856de
- The paper
- Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010). A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181c856de
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.